曲美他嗪对冠状动脉介入术后心肌缺血再灌注损伤的保护作用研究

余强; 张大东

曲美他嗪对冠状动脉介入术后心肌缺血再灌注损伤的保护作用研究

余强,
张大东

1.
上海瑞金医院集团闵行区中心医院心血管内科

作者简介: 余强(1964-)，男，副主任医师．

基金项目:
上海市闵行区科委资助项目(2009MHZ068)

Protective effect of trimetazidine on myocardial injury by percutaneous coronary intervention

1.
Department of Cardiology，Minhang District Central Hospital，Affiliated Hospital of Shanghai Ruijin Group，Shanghai 201199，China

摘要: 目的:评价曲美他嗪对冠状动脉介入术(PCI)后心肌缺血再灌注损伤的保护作用。方法:入选拟行PCI的稳定性或不稳定性心绞痛患者72例，随机分为曲美他嗪组38例和对照组34例，曲美他嗪组PCI术前7 d开始口服曲美他嗪20 mg，每天3次，术后继续服用3个月;所有入选患者给予阿司匹林及常规药物治疗。每例在PCI术前及术后6、24 h测定血清肌钙蛋白I(cTnI)、磷酸肌酸激酶同工酶(CK-MB);在PCI术前及术后1、3个月分别超声心动图测定左室射血分数。结果:术前2组患者cTnI、CK-MB水平差异均无统计学意义(P0.05)，与对照组比较，PCI术后曲美他嗪组在各个测量时段均能显著降低患者cTnI、CK-MB水平(P0.01)，PCI术后1、3个月曲美他嗪组左室射血分数值均高于对照组(P0.01)。结论:PCI术前应用曲美他嗪能显著降低手术诱导的心肌损害，进一步改善PCI术后的左心功能。
- 心肌疾病 /
- 曲美他嗪 /
- 心绞痛 /
- 经皮冠状动脉介入术
Abstract: Objective：To evaluate the protective effect of trimetazidine on myocardial injury by percutaneous coronary intervention(PCI).Methods：Seventy-two cases with stable or unstable angina were randomly divided into control group(n=34) and trimetazidine group(n=38).Treatment group received trimetazidine of 20 mg three times a day for 7 days before PCI) and Continuous oral three months after PCI.Control group did not receive trimetazidine.All cases(n=72) were administered aspirin and conventional drugtreatment.The cardiac troponin Ic(cTnI) and creatine kinase-MB(CK-MB) levels of each case were measured at 6,24 hour and left ventricular ejection fraction were also detcted at 1,3 month before and after PCI.Results：In all cases,the cardiac troponin Ic(cTnI) and creatine kinase-MB(CK-MB) levels had no significantly difference(P〉0.05)before PCI,but its levels of trimetazidine group were also significantly lower than that of control group throughout procedure after PCI.Left ventricular ejection levels of trimetazidine group were also significantly higher than control group at 1,3 month after PCI(P〈0.01).Conclusions：Using trimetazidine before PCI can significantly reduce myocardial injury PCI-induced,and improves left ventricular contractility function.
- myocardial disease /
- trimetazidine /
- stable /
- percutaneous coronary intervention

[1]
[2]	《曲美他嗪治疗冠心病合并左心功能不全患者的疗效研究》[J].中华心血管病杂志,2005(9).
[2] Antman EM,Anbe DT,Armstrong ER,et al.ACC/AHAguidelines for the management of patients with ST-elevationmyocardial infarction[J].Circulation,2004,110(5):588-636.
[4]
[3] Fox KA,Poole-Wilson PA,Henderson RA,et al.Interventionalversus conservative treatment for patients with unstable angina ornon-ST elevation myocardial infarction[J].Lancet,2002,360(9335):743-751.
[6]
[4] Boden WE,O'Rourke RA,Teo KK,et al.COURAGE TrialResearch Group.Optimal medical therapy with or without PCI forstable coronary disease[J].N Engl J Med,2007,356(15):1503-1516.
[8]
[5] Yellon DM,Hausenloy D.Myocardial reperfusion injury[J].NEngl J Med,2007,357(11):1121-1135.
[10]
[6] Kober G,Buck T,Sievert H,et al.Myocardial protection duringpercutaneous transluminal coronary angioplasty;Effects oftrimetazidine[J].Euro Heart J,1992,13(8):1109-1115.
[12]
[7] Aussedet J,Ray A,Kay L,et al.Improvement of long-termpreservation of isolated tat heart:beneficial effect of theantiischemic agent trimetazidine[J].J Cardiovasc Pharmacol,1993,21(6):128-135.
[14]
[8] Stanley WC,Lopaschuk GD,Hall JL,et al.Regulation ofmyocardial carbohydrate metabolism under normal and ischaemecconditions.Potential for pharmacological interventions[J].Cardiovasc Res,1997,33(2):243-257.
[16]
[9] Desideri A,Celegon L.Metabolic management of ischemic heartdisease:clinical data with trimetazidine[J].Am Cardiol,1998,82(5A):50K-53K.＜br＞
[10] Guarnieri C,Muscari C.Effect of trimetazidine on mitochondrialfunction and oxidative damage during reperfusion of ischemichypertrophied rat myocardium[J].Pharmacology,1993,46(6):324-331.
[19]
[11] Williams FM,Tanda K,Kus M,et al.Trimetazidine inhibitsneutrophil accumulation after myocardial ischemia andreperfusion in rabbits[J].J Cardiovasc Pharmacol,1993,22(6):828-833.
[21]
[12] Bertomeu Gonzalez V,Bouzas Mosquera A,Kaski JC.Role oftrimetazidine in management of ischemic cardiomyopathy[J].AmJ Cardiol,2006,98(5A):19-24.
[23]
[13] Polonski L,Dec I,Wojnar R,et al.Trimetazidine limits the effectsof myocardial ischaemia during percutaneous coronary angioplasty[J].Curr Medi Res Opin,2002,18(7):389-396.
[25]
[14] Bonello L,Sbragia P,Amabile N,et al.Protective effect of anacute oral loading dose of Trimetazidine on myocardial injuryfollowing percutaneous coronary intervention[J].Heart,2007,93(6):703-707.
[27]
[15] Labrou A,Ciannoglou G,Zioutas D,et al.Trimetazidineadministration minimizes myocardial damage and improves leftventricular function after percutaneous coronary intervention[J].Am J Cardiovasc Drugs,2007,7(2):143-150.

[1]	杨秋菊 , 蔡鑫 . 经皮激光心肌血运重建术治疗顽固性心绞痛的研究进展. 蚌埠医学院学报, 2013, 37(6): 775-777.
[2]	梁鹏 , 周新华 , 陈开祥 , 刘步祥 , 孙成爱 , 张黎黎 . 曲美他嗪治疗脓毒症心肌损伤的临床研究. 蚌埠医学院学报, 2016, 41(11): 1443-1445. doi: 10.13898/j.cnki.issn.1000-2200.2016.11.011
[3]	韩宏华 , 陈大顺 . 女性心绞痛患者冠状动脉造影结果分析. 蚌埠医学院学报, 2006, 31(1): 53-54.
[4]	陈坚 , 王正东 , 李平 , 甘剑挺 , 谢文超 . 急性心肌梗死病人经皮冠状动脉介入术后对比剂肾病的危险因素分析. 蚌埠医学院学报, 2017, 42(9): 1183-1185,1189. doi: 10.13898/j.cnki.issn.1000-2200.2017.09.009
[5]	梁伟华 . 瑞舒伐他汀钙与氯吡格雷联合治疗不稳定型心绞痛的疗效分析. 蚌埠医学院学报, 2015, 40(6): 743-745. doi: 10.13898/j.cnki.issn.1000-2200.2015.06.014
[6]	周彤 , 周成超 , 唐碧 , 王洪巨 , 王莉媛 , 张晓玲 . 急性心肌梗死患者经皮冠状动脉介入术后自我管理水平的调查研究. 蚌埠医学院学报, 2016, 41(1): 126-129. doi: 10.13898/j.cnki.issn.1000-2200.2016.01.041
[7]	吴纲 . 新活素对急性心肌梗死并发心力衰竭病人经皮冠状动脉介入术后预后的影响. 蚌埠医学院学报, 2022, 47(8): 1070-1073. doi: 10.13898/j.cnki.issn.1000-2200.2022.08.019
[8]	谢伟 , 袁争百 , 苏振琪 , 韩宏华 , 陈大顺 . 急性ST段抬高型心肌梗死经皮冠状动脉介入开通闭塞血管时间的影响因素. 蚌埠医学院学报, 2015, 40(3): 372-374. doi: 10.13898/j.cnki.issn.1000-2200.2015.03.026
[9]	李玉忠 , 吴霭青 . 不同剂量右美托咪定用于急性冠状动脉综合征PCI介入效果分析. 蚌埠医学院学报, 2016, 41(5): 616-618. doi: 10.13898/j.cnki.issn.1000-2200.2016.05.020
[10]	冯琴 , 许丽 , 郑桂香 , 赵培 , 焦云根 , 周艳 , 袁晓晨 , 朱莹 . 中青年急性心肌梗死病人冠状动脉介入术后应激障碍症状群的研究及干预策略. 蚌埠医学院学报, 2022, 47(5): 672-674. doi: 10.13898/j.cnki.issn.1000-2200.2022.05.029
[11]	竟雪莹 , 祖磊 . 不同剂量阿托伐他汀对急性冠状动脉综合征患者PCI术后炎症因子的影响. 蚌埠医学院学报, 2013, 37(9): 1103-1104,1107.
[12]	许春奇 , 孙得永 , 吕秀英 , 程仁力 , 程琼 . 曲美他嗪治疗急性缺血性血管性痴呆疗效分析. 蚌埠医学院学报, 2015, 40(10): 1360-1363.
[13]	汤凤英 , 马礼坤 , 石增刚 , 桑更生 . 急性冠状动脉综合征患者血清可溶性E-选择素和白介素-10水平的变化及其与冠状动脉病变程度的相关性. 蚌埠医学院学报, 2010, 35(5): 456-458.
[14]	陈启 , 马礼坤 , 孙向东 , 桑更生 , 吴金 . 冠心病患者血清脂联素、YKL-40水平的变化及其与冠状动脉病变程度的关系. 蚌埠医学院学报, 2010, 35(4): 361-363,366.
[15]	岳芳 . 综合护理干预应用于冠心病心绞痛患者的效果观察. 蚌埠医学院学报, 2014, 38(6): 835-836.
[16]	刘明 , 朱伦华 , 牛俊彦 , 刘洪俊 . 急性心肌梗死血清C反应蛋白检测临床意义探讨. 蚌埠医学院学报, 2010, 35(9): 931-932.
[17]	竟雪莹 , 石增刚 , 张乐 , 解霞 . 静脉水化疗法预防经皮冠状动脉介入术后造影剂肾病. 蚌埠医学院学报, 2011, 36(7): 719-721.
[18]	竟雪莹 , 余强 . 经皮冠状动脉介入术对冠心病患者心率变异性的影响. 蚌埠医学院学报, 2006, 31(5): 489-490.
[19]	邹玲 , 谢娟 , 范春梅 . 老年冠心病经皮冠状动脉介入术后病人个人掌控感现状及影响因素分析. 蚌埠医学院学报, 2023, 48(6): 824-828. doi: 10.13898/j.cnki.issn.1000-2200.2023.06.026
[20]	潘正群 , 范秀珍 . 经皮冠状动脉介入治疗患者心理应对方式和应对能力的相关性研究. 蚌埠医学院学报, 2011, 36(5): 523-527.

点击查看大图

计量

文章访问数: 3644
HTML全文浏览量: 425
PDF下载量: 408
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

曲美他嗪对冠状动脉介入术后心肌缺血再灌注损伤的保护作用研究

作者简介: 余强(1964-)，男，副主任医师．

Protective effect of trimetazidine on myocardial injury by percutaneous coronary intervention

计量

曲美他嗪对冠状动脉介入术后心肌缺血再灌注损伤的保护作用研究

作者简介: 余强(1964-)，男，副主任医师．

English Abstract

Protective effect of trimetazidine on myocardial injury by percutaneous coronary intervention

全文HTML

目录

留言板

曲美他嗪对冠状动脉介入术后心肌缺血再灌注损伤的保护作用研究

作者简介: 余强(1964-)，男，副主任医师．

Protective effect of trimetazidine on myocardial injury by percutaneous coronary intervention

计量

出版历程

曲美他嗪对冠状动脉介入术后心肌缺血再灌注损伤的保护作用研究

作者简介: 余强(1964-)，男，副主任医师．

English Abstract

Protective effect of trimetazidine on myocardial injury by percutaneous coronary intervention

全文HTML

目录